Brief: Jasper Announces First Patient Dosed In Phase 1B/2A Clinical Study Of Briquilimab In Chronic Spontaneous Urticaria
30/11/2023 13:09
Jasper Therapeutics Inc JSPR.O :
* JASPER ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B/2A
CLINICAL
STUDY OF BRIQUILIMAB IN CHRONIC SPONTANEOUS URTICARIA
* JASPER THERAPEUTICS - LOOK FORWARD TO PROVIDING ENROLLMENT
UPDATES AS WE PROGRESS THROUGH COHORTS & ANTICIPATE REPORTING
PRELIMINARY DATA IN MID-2024
Source text for Eikon: ID:nGNX7Q0G4p
Further company coverage: JSPR.O
Recent news on Jasper Therapeutics
See all newsBrief: Jasper Therapeutics Announces Commencement Of An Offer To Purchase Outstanding Warrants
Jasper Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln
Jasper Therapeutics, Inc. expected to post a loss of 35 cents a share - Earnings Preview
Jasper Therapeutics rises; co announces all-stock merger with Kira Pharma